Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment

Brent D. Weinberg, Elvin Blanco, Scott F. Lempka, James M. Anderson, Agata A. Exner, Jinming Gao

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Previously, biodegradable polymer implants (polymer millirods) to release chemotherapeutic agents directly into tumors have been developed. The purpose of this study is to evaluate local drug distribution from these implants in liver tumors treated with radiofrequency (RF) ablation and determine if the implants provide a therapeutic improvement over RF ablation alone. Cylindrical implants were fabricated using 65% poly(D,L-lactide-co-glycolide) (PLGA), 21.5% NaCl, and 13.5% doxorubicin. Control or drug-containing millirods were implanted inside VX2 liver tumors (11 mm diameter) in rabbits after RF ablation. Therapeutic efficacy was assessed 4 and 8 days after treatment using tumor size, histology, and fluorescence measurement of drug distribution. Tumors in both test groups recurred at the boundary of the ablated region. Therapeutic doxorubicin concentrations were found in more than 80% of the ablated area, but concentrations declined rapidly at the boundary between normal and ablated tissue. This region was characterized by a developing fibrous capsule with resolving inflammation, which restricted drug transport out of the ablated zone. The intratumoral doxorubicin implants delivered high concentrations of drug within the ablated region but only limited amounts outside the ablation zone. Future studies will focus on overcoming the fibrotic transport barrier and enhancing drug delivery to the periphery of the ablation region to prevent tumor progression.

Original languageEnglish (US)
Pages (from-to)205-213
Number of pages9
JournalJournal of Biomedical Materials Research - Part A
Volume81
Issue number1
DOIs
StatePublished - Apr 2007

Fingerprint

Oncology
Ablation
Liver
Doxorubicin
Tumors
Polymers
Pharmaceutical Preparations
Biodegradable polymers
Histology
Drug delivery
Capsules
Fluorescence
Tissue

Keywords

  • Biodegradable polymer
  • Intratumoral drug delivery
  • Minimally invasive therapy
  • Polymer implants
  • VX2 tumor

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. / Weinberg, Brent D.; Blanco, Elvin; Lempka, Scott F.; Anderson, James M.; Exner, Agata A.; Gao, Jinming.

In: Journal of Biomedical Materials Research - Part A, Vol. 81, No. 1, 04.2007, p. 205-213.

Research output: Contribution to journalArticle

Weinberg, Brent D. ; Blanco, Elvin ; Lempka, Scott F. ; Anderson, James M. ; Exner, Agata A. ; Gao, Jinming. / Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. In: Journal of Biomedical Materials Research - Part A. 2007 ; Vol. 81, No. 1. pp. 205-213.
@article{8325f3b7b2eb4c5cadd6645177365a8d,
title = "Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment",
abstract = "Previously, biodegradable polymer implants (polymer millirods) to release chemotherapeutic agents directly into tumors have been developed. The purpose of this study is to evaluate local drug distribution from these implants in liver tumors treated with radiofrequency (RF) ablation and determine if the implants provide a therapeutic improvement over RF ablation alone. Cylindrical implants were fabricated using 65{\%} poly(D,L-lactide-co-glycolide) (PLGA), 21.5{\%} NaCl, and 13.5{\%} doxorubicin. Control or drug-containing millirods were implanted inside VX2 liver tumors (11 mm diameter) in rabbits after RF ablation. Therapeutic efficacy was assessed 4 and 8 days after treatment using tumor size, histology, and fluorescence measurement of drug distribution. Tumors in both test groups recurred at the boundary of the ablated region. Therapeutic doxorubicin concentrations were found in more than 80{\%} of the ablated area, but concentrations declined rapidly at the boundary between normal and ablated tissue. This region was characterized by a developing fibrous capsule with resolving inflammation, which restricted drug transport out of the ablated zone. The intratumoral doxorubicin implants delivered high concentrations of drug within the ablated region but only limited amounts outside the ablation zone. Future studies will focus on overcoming the fibrotic transport barrier and enhancing drug delivery to the periphery of the ablation region to prevent tumor progression.",
keywords = "Biodegradable polymer, Intratumoral drug delivery, Minimally invasive therapy, Polymer implants, VX2 tumor",
author = "Weinberg, {Brent D.} and Elvin Blanco and Lempka, {Scott F.} and Anderson, {James M.} and Exner, {Agata A.} and Jinming Gao",
year = "2007",
month = "4",
doi = "10.1002/jbm.a.30926",
language = "English (US)",
volume = "81",
pages = "205--213",
journal = "Journal of Biomedical Materials Research - Part A",
issn = "0021-9304",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment

AU - Weinberg, Brent D.

AU - Blanco, Elvin

AU - Lempka, Scott F.

AU - Anderson, James M.

AU - Exner, Agata A.

AU - Gao, Jinming

PY - 2007/4

Y1 - 2007/4

N2 - Previously, biodegradable polymer implants (polymer millirods) to release chemotherapeutic agents directly into tumors have been developed. The purpose of this study is to evaluate local drug distribution from these implants in liver tumors treated with radiofrequency (RF) ablation and determine if the implants provide a therapeutic improvement over RF ablation alone. Cylindrical implants were fabricated using 65% poly(D,L-lactide-co-glycolide) (PLGA), 21.5% NaCl, and 13.5% doxorubicin. Control or drug-containing millirods were implanted inside VX2 liver tumors (11 mm diameter) in rabbits after RF ablation. Therapeutic efficacy was assessed 4 and 8 days after treatment using tumor size, histology, and fluorescence measurement of drug distribution. Tumors in both test groups recurred at the boundary of the ablated region. Therapeutic doxorubicin concentrations were found in more than 80% of the ablated area, but concentrations declined rapidly at the boundary between normal and ablated tissue. This region was characterized by a developing fibrous capsule with resolving inflammation, which restricted drug transport out of the ablated zone. The intratumoral doxorubicin implants delivered high concentrations of drug within the ablated region but only limited amounts outside the ablation zone. Future studies will focus on overcoming the fibrotic transport barrier and enhancing drug delivery to the periphery of the ablation region to prevent tumor progression.

AB - Previously, biodegradable polymer implants (polymer millirods) to release chemotherapeutic agents directly into tumors have been developed. The purpose of this study is to evaluate local drug distribution from these implants in liver tumors treated with radiofrequency (RF) ablation and determine if the implants provide a therapeutic improvement over RF ablation alone. Cylindrical implants were fabricated using 65% poly(D,L-lactide-co-glycolide) (PLGA), 21.5% NaCl, and 13.5% doxorubicin. Control or drug-containing millirods were implanted inside VX2 liver tumors (11 mm diameter) in rabbits after RF ablation. Therapeutic efficacy was assessed 4 and 8 days after treatment using tumor size, histology, and fluorescence measurement of drug distribution. Tumors in both test groups recurred at the boundary of the ablated region. Therapeutic doxorubicin concentrations were found in more than 80% of the ablated area, but concentrations declined rapidly at the boundary between normal and ablated tissue. This region was characterized by a developing fibrous capsule with resolving inflammation, which restricted drug transport out of the ablated zone. The intratumoral doxorubicin implants delivered high concentrations of drug within the ablated region but only limited amounts outside the ablation zone. Future studies will focus on overcoming the fibrotic transport barrier and enhancing drug delivery to the periphery of the ablation region to prevent tumor progression.

KW - Biodegradable polymer

KW - Intratumoral drug delivery

KW - Minimally invasive therapy

KW - Polymer implants

KW - VX2 tumor

UR - http://www.scopus.com/inward/record.url?scp=33947192941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947192941&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.30926

DO - 10.1002/jbm.a.30926

M3 - Article

VL - 81

SP - 205

EP - 213

JO - Journal of Biomedical Materials Research - Part A

JF - Journal of Biomedical Materials Research - Part A

SN - 0021-9304

IS - 1

ER -